vs
EXACT SCIENCES CORP（EXAS）与Regions Financial Corporation（RF）财务数据对比。点击上方公司名可切换其他公司
Regions Financial Corporation的季度营收约是EXACT SCIENCES CORP的1.5倍（$1.3B vs $878.4M），Regions Financial Corporation净利率更高（41.7% vs -9.8%，领先51.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs 4.1%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 4.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Regions Financial Corporation是美国银行控股企业，总部位于阿拉巴马州伯明翰市。公司提供零售及商业银行、信托、股票经纪、抵押贷款等服务，旗下银行业务子公司Regions Bank在美国南部和中西部15个州运营约1300家营业网点和2000台自动柜员机，服务大量当地个人及企业客户。
EXAS vs RF — 直观对比
营收规模更大
RF
是对方的1.5倍
$878.4M
营收增速更快
EXAS
高出19.0%
4.1%
净利率更高
RF
高出51.5%
-9.8%
两年增速更快
EXAS
近两年复合增速
4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.3B |
| 净利润 | $-86.0M | $534.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 55.3% |
| 净利率 | -9.8% | 41.7% |
| 营收同比 | 23.1% | 4.1% |
| 净利润同比 | 90.1% | 0.0% |
| 每股收益（稀释后） | $-0.45 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRF
| Q4 25 | $878.4M | $1.3B | ||
| Q3 25 | $850.7M | $1.3B | ||
| Q2 25 | $811.1M | $1.3B | ||
| Q1 25 | $706.8M | $1.2B | ||
| Q4 24 | $713.4M | $1.2B | ||
| Q3 24 | $708.7M | $1.2B | ||
| Q2 24 | $699.3M | $1.2B | ||
| Q1 24 | $637.5M | $1.2B |
净利润EXASRF
| Q4 25 | $-86.0M | $534.0M | ||
| Q3 25 | $-19.6M | $569.0M | ||
| Q2 25 | $-1.2M | $563.0M | ||
| Q1 25 | $-101.2M | $490.0M | ||
| Q4 24 | $-864.6M | $534.0M | ||
| Q3 24 | $-38.2M | $490.0M | ||
| Q2 24 | $-15.8M | $501.0M | ||
| Q1 24 | $-110.2M | $368.0M |
毛利率EXASRF
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASRF
| Q4 25 | -9.4% | 55.3% | ||
| Q3 25 | -3.0% | 56.3% | ||
| Q2 25 | -0.3% | 56.1% | ||
| Q1 25 | -13.6% | 52.0% | ||
| Q4 24 | -122.8% | 53.4% | ||
| Q3 24 | -5.6% | 49.9% | ||
| Q2 24 | -3.8% | 52.7% | ||
| Q1 24 | -16.7% | 39.2% |
净利率EXASRF
| Q4 25 | -9.8% | 41.7% | ||
| Q3 25 | -2.3% | 45.3% | ||
| Q2 25 | -0.1% | 44.7% | ||
| Q1 25 | -14.3% | 41.0% | ||
| Q4 24 | -121.2% | 43.4% | ||
| Q3 24 | -5.4% | 40.2% | ||
| Q2 24 | -2.3% | 42.2% | ||
| Q1 24 | -17.3% | 31.1% |
每股收益（稀释后）EXASRF
| Q4 25 | $-0.45 | $0.59 | ||
| Q3 25 | $-0.10 | $0.61 | ||
| Q2 25 | $-0.01 | $0.59 | ||
| Q1 25 | $-0.54 | $0.51 | ||
| Q4 24 | $-4.69 | $0.55 | ||
| Q3 24 | $-0.21 | $0.49 | ||
| Q2 24 | $-0.09 | $0.52 | ||
| Q1 24 | $-0.60 | $0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | $4.1B |
| 股东权益账面价值 | $2.4B | $19.0B |
| 总资产 | $5.9B | $158.8B |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资EXASRF
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | — |
总债务EXASRF
| Q4 25 | — | $4.1B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.3B | ||
| Q1 25 | — | $6.0B | ||
| Q4 24 | — | $6.0B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | — | $5.1B | ||
| Q1 24 | — | $3.3B |
股东权益EXASRF
| Q4 25 | $2.4B | $19.0B | ||
| Q3 25 | $2.5B | $19.0B | ||
| Q2 25 | $2.5B | $18.7B | ||
| Q1 25 | $2.4B | $18.5B | ||
| Q4 24 | $2.4B | $17.9B | ||
| Q3 24 | $3.2B | $18.7B | ||
| Q2 24 | $3.2B | $17.2B | ||
| Q1 24 | $3.1B | $17.0B |
总资产EXASRF
| Q4 25 | $5.9B | $158.8B | ||
| Q3 25 | $5.9B | $159.9B | ||
| Q2 25 | $5.8B | $159.2B | ||
| Q1 25 | $5.7B | $159.8B | ||
| Q4 24 | $5.9B | $157.3B | ||
| Q3 24 | $6.7B | $157.4B | ||
| Q2 24 | $6.7B | $154.1B | ||
| Q1 24 | $6.4B | $154.9B |
负债/权益比EXASRF
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.25× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 0.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-319.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | -0.60× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRF
| Q4 25 | $151.7M | $-319.0M | ||
| Q3 25 | $219.9M | $861.0M | ||
| Q2 25 | $89.0M | $573.0M | ||
| Q1 25 | $30.8M | $1.1B | ||
| Q4 24 | $47.1M | $-220.0M | ||
| Q3 24 | $138.7M | $1.3B | ||
| Q2 24 | $107.1M | $161.0M | ||
| Q1 24 | $-82.3M | $396.0M |
自由现金流EXASRF
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASRF
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASRF
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASRF
| Q4 25 | — | -0.60× | ||
| Q3 25 | — | 1.51× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 2.18× | ||
| Q4 24 | — | -0.41× | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 0.32× | ||
| Q1 24 | — | 1.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RF
| Consumer Bank | $747.0M | 58% |
| Corporate Bank | $487.0M | 38% |
| Wealth Management | $47.0M | 4% |
